TRITEC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRITEC (TRITEC).
H2-receptor antagonist; competitively inhibits histamine at H2 receptors of gastric parietal cells, reducing basal and stimulated gastric acid secretion.
| Metabolism | Hepatic via N-demethylation and S-oxidation; minor metabolism by CYP450; excreted renally as unchanged drug and metabolites. |
| Excretion | Renal: 60% unchanged; fecal: 35% (mainly metabolites) |
| Half-life | 2-3 hours (prolonged to 4-5 hours in elderly or renal impairment, CrCl <30 mL/min) |
| Protein binding | 93% (bound to albumin) |
| Volume of Distribution | 1.5 L/kg (indicating extensive tissue distribution) |
| Bioavailability | Oral: 65-70% (due to first-pass metabolism); Topical: negligible systemic absorption (approximately 1.5%) |
| Onset of Action | Oral: 1 hour; Topical: 2-3 weeks for significant hair regrowth |
| Duration of Action | 8-12 hours after single dose; topical: continuous use required to maintain effect |
300 mg orally twice daily for 14 days; alternative: 600 mg orally once daily for 14 days.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (CrCl <10 mL/min), use with caution; dose reduction to 150 mg once daily may be considered. |
| Liver impairment | No specific dose adjustment recommended for hepatic impairment; use with caution in severe hepatic dysfunction. |
| Pediatric use | Not recommended for use in pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | No specific dose adjustment required, but monitor for adverse effects due to potential age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRITEC (TRITEC).
| Breastfeeding | Excreted in breast milk; M/P ratio not reported. Use caution due to potential for infant diarrhea and rash. |
| Teratogenic Risk | FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; insufficient human data. Avoid first trimester use unless clearly needed. |
| Fetal Monitoring | Monitor maternal renal function and electrolytes; fetal ultrasound if used during pregnancy. |
■ FDA Black Box Warning
Not available
| Serious Effects |
["Hypersensitivity to ranitidine or any H2-receptor antagonist","Acute porphyria","Concurrent use with nitrosating agents (theoretical cancer risk due to formation of N-nitrosamines)"]
| Precautions | ["May cause confusion, delirium, hallucinations, especially in elderly or renally impaired patients","Risk of acute porphyria; avoid in patients with porphyria","May mask symptoms of gastric malignancy","Adjust dose in renal impairment (CrCl <50 mL/min)","Potential for neuropsychiatric events (reversible with discontinuation)","Hypersensitivity reactions (rare)"] |
Loading safety data…
| Fertility Effects | No known effect on fertility in animal studies; limited human data. |